Drug Profile
Research programme: TRPV1 antagonists - Merck
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Schering-Plough
- Developer Merck & Co
- Class Isoxazoles
- Mechanism of Action TRPV1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in United Kingdom (PO)
- 26 Mar 2009 Preclinical trials in Pain in United Kingdom (PO)